Search results
Oct 19, 2023 · A large new study links COVID-19 with an increased risk of Guillain-Barré syndrome (GBS). Vaccination against COVID appeared to reduce the risk of GBS, which is a rare illness that can...
Oct 18, 2023 · A new study from Israel ties COVID-19 infection to an increased risk of a diagnosis of Guillain-Barre syndrome (GBS) within 6 weeks, while mRNA vaccination was linked to a decreased risk of the rare but serious autoimmune disease.
Apr 26, 2022 · In this cohort study’s interim analyses conducted in a large population-based surveillance system that included medical record review of all potential GBS cases after COVID-19 vaccination through November 13, 2021, findings were consistent with an increased risk of GBS after Ad.26.COV2.S.
National and international vaccine guidelines did not preclude patients who have previously been diagnosed with Guillain-Barré Syndrome (GBS) from receiving the COVID-19 vaccine. 1, 2 However, previous association between vaccines and GBS raises the level of caution and hesitancy among clinicians and patients regarding administering the vaccine....
Jul 12, 2021 · “Guillain Barré syndrome (a neurological disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who have...
Oct 23, 2023 · Existing data regarding occurrence of Guillain-Barré syndrome (GBS) after coronavirus disease 2019 (COVID-19) infection and vaccination are inconclusive. We aimed to assess the association between GBS and both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 vaccine.
Dec 17, 2021 · We report the findings of two patients with Guillain-Barré syndrome after receiving the BNT162b2 vaccine (tozinameran, Pfizer–BioNTech) who were in complete remission from diffuse large B-cell lymphoma.
Nov 2, 2023 · A nested case-control study from Israel that followed more than 3 million patients found that those who became infected with COVID-19 had an increased risk of developing Guillain-Barré Syndrome (GBS), but that risk dropped in those who received the Pfizer-BioNTech vaccine.
Guillain-Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy with a ≈5% mortality rate, has an incidence worldwide of 0.81–1.91 cases/100,000 person-years . GBS has been reported to be associated with coronavirus disease (COVID-19) vaccination, but a comprehensive summary regarding this rare adverse event is still lacking.
- www.ncbi.nlm.nih.gov
- › …
- › Brain Behav Immun Health
- › v.28; 2023 Mar
Jan 17, 2023 · During this period, it has been learned that various manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can affect the nervous system. In recent months, a variety of studies and case reports have proposed an association between COVID-19 and Guillain–Barré syndrome (GBS).
